摘要:
The invention is concerned with novel imidazopyrimidine derivatives of formula (I) wherein R1, R2 and R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.
摘要:
The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR δ and/or PPARα agonists.
摘要:
The invention is concerned with novel imidazolidinone derivatives of formula (I): wherein R1 to R11 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used in pharmaceutical compositions.
摘要:
The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R1 to R6, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.
摘要:
The invention is concerned with novel imidazolidinone derivatives of formula (I): wherein R1 to R11 and X are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used in pharmaceutical compositions.
摘要:
A sealing structure in a fuel cell and/or an electrolyzer (particularly a solid-oxide fuel cell and/or a solid-oxide electrolyzer) is arranged between neighboring separator plates of a cell stack. The sealing structure is constructed in at least two layers, including at least one insulating layer and at least one sealing layer.
摘要:
The invention relates to a fuel cell stack which is composed of several individual fuel cells that are stacked on top of each other. Each of said fuel cells comprises a cathode-electrolyte-anode unit (7) and a perforated film (1) which distributes a combustible gas across the first electrode surface thereof, supports the cathode-electrolyte-anode unit (7), and is combined into a cassette (4) that is provided with a hollow space along with an additional structure (3). The combustible gas reaches the first electrode (7A) via said cassette (4). The side of each cassette (4), which is located opposite the cathode-electrolyte-anode unit (7), is provide with a structure for distributing atmospheric oxygen across the surface of the second electrode of a neighboring cassette such that the stack is formed by several superimposed cassettes (4), between the film (1) of which a cathode-electrolyte-anode unit (7) and the structure for distributing atmospheric oxygen across the surface of the second electrode are disposed along with the additional structure (3). In order to brace the individual cassettes against each other in a housing or similar, the inventive stack comprises at least one bracing cassette, the walls of which are impermeable and which is filled with a material that expands to a relatively great extent when being heated.
摘要:
The invention is concerned with novel fused pyrrole derivatives of formula (I) wherein A, Ar, R1, R2, R2′ and R2″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.
摘要:
This invention is concerned with compounds of the formula wherein one of R5, R6 and R7 is and R1 to R13, X1, X2, m and n are defined in the description, and all pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.
摘要:
The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.